Pharmacogenomics, Special Populations & CIOMS
The final unit of Pharmacovigilance addresses the immense variability of human biology. It explores how Pharmacogenomics (genetic mutations) drastically alters drug metabolism, directly causing terrifying ADRs in specific populations. You will then study the critical dangers of prescribing to ‘Special Populations’ who are biologically distinct (Neonates, Pregnant women, Geriatrics). Finally, it covers the global reporting influence of CIOMS and India’s precise regulatory framework, Schedule Y of the CDSCO.
Syllabus & Topics
- 1Pharmacogenomics of Adverse Drug Reactions: Pharmacogenomics: The study of how an individual’s distinct genetic makeup affects their body’s response to drugs. Mechanism: Genetic polymorphism deeply dictates Pharmacokinetic parameters (specifically genetic mutations in Cytochrome P450 liver enzymes). Example: If a patient genetically lacks the CYP2D6 enzyme, they are a ‘Poor Metabolizer’. If given a standard dose of a drug heavily cleared by CYP2D6, the drug massively accumulates in their blood, causing severe, fatal toxicity instead of therapy. Conversely, ‘Ultra-rapid Metabolizers’ clear the drug instantly, leading to therapeutic failure.
- 2Drug Safety Evaluation in Special Populations – Pediatrics: Why they are special: Children are not just ‘tiny adults’. Neonates have radically underdeveloped livers, kidneys, and blood-brain barriers. Standard Pharmacokinetic formulas often fail. Because clinical trials rarely experiment on children (ethical reasons), pediatric prescribing is notoriously ‘Off-Label’, relying purely on post-market pharmacovigilance to desperately catch terrible pediatric ADRs (e.g., Grey Baby Syndrome from Chloramphenicol).
- 3Drug Safety Evaluation in Pregnancy and Lactation: The absolute highest risk population. Thalidomide proved the placental barrier is highly permeable. Teratogenicity: The ability of a drug to induce gross structural malformations in a growing fetus, primarily during the critical First Trimester (organogenesis). FDA Pregnancy Categories (A, B, C, D, X) are used to classify absolute fetal risk versus maternal benefit. Lactation: Assessing whether lipid-soluble drugs enter breast milk and poison the nursing infant.
- 4Drug Safety Evaluation in Geriatrics (Elderly): As humans age past 65, total body water decreases, body fat increases, and most critically, renal (kidney) clearance drastically plummets. Therefore, standard adult doses dangerously accumulate in the elderly. Polypharmacy: The compounding danger that an elderly patient with multiple morbidities takes 8-10 massive medications simultaneously, exponentially increasing the mathematical probability of a severe Drug-Drug Interaction and toxic ADR.
- 5CIOMS and Pharmacovigilance: CIOMS (Council for International Organizations of Medical Sciences): An international NGO established by WHO and UNESCO in 1949. Working Groups: CIOMS formed brilliant working groups that essentially wrote the foundational templates for global Pharmacovigilance. CIOMS Form: Form-I. The universally recognized pioneer, standardized, 1-page form for reporting suspected Severe Adverse Drug Reactions globally, predating modern fully-electronic E2B systems.
- 6CDSCO (India) and Pharmacovigilance: Central Drugs Standard Control Organisation is India’s national regulatory body (headed by the DCGI). Drugs and Cosmetics Act (Schedule Y): Schedule Y specifically deals with the legal requirements and guidelines for conducting Clinical Trials and generating massive safety/efficacy data in India. It mandates strict reporting of SAEs (Serious Adverse Events) during Indian clinical trials. Indian Requirements vs Global: While moving towards ICH harmonization via PvPI, India historically had a highly fragmented safety reporting culture compared to the strict, heavily digitized, mathematically sophisticated signal-detection systems of Europe (EMA) and the USA (USFDA).
Learning Objectives
Exam Prep Questions
Q1. What does it mean to be an “Ultra-Rapid Metabolizer” in Pharmacogenomics?
An ultra-rapid metabolizer is a person who has multiple copies of certain drug-metabolizing enzyme genes, such as CYP2D6. Because of this genetic variation, their liver produces a much higher amount of the enzyme than normal.
As a result, the drug is metabolized extremely quickly, often before it can reach effective concentrations in the bloodstream or target tissues. When such individuals take standard doses of medications (for example certain antidepressants or analgesics), the drug may be cleared too rapidly, leading to therapeutic failure despite correct dosing.
Q2. Why do many drugs cause toxicity or “Gray Baby Syndrome” in neonates?
Newborn infants have immature liver enzyme systems, particularly low activity of enzymes such as glucuronyl transferase (UDP-glucuronosyltransferase). These enzymes are necessary for drug conjugation and detoxification.
Because neonates cannot efficiently metabolize certain drugs, the medication accumulates in the bloodstream instead of being safely eliminated. With drugs such as Chloramphenicol, this accumulation can lead to Gray Baby Syndrome, characterized by cardiovascular collapse, abdominal distension, cyanosis, and potentially fatal toxicity.
Q3. What is the historical significance of the “CIOMS-I Form”?
Before standardized pharmacovigilance reporting systems existed, adverse drug reaction reports were submitted in different formats, languages, and data requirements across countries. This lack of uniformity made global safety monitoring slow and inefficient.
The CIOMS-I Form, developed by the Council for International Organizations of Medical Sciences (CIOMS), created a standardized international template for reporting suspected adverse drug reactions. It defined the essential minimum information required for a valid report:
An identifiable patient
An identifiable reporter
A suspected drug
An adverse event
This standardization greatly improved global pharmacovigilance communication and served as the foundation for modern electronic safety reporting systems.